Q4 2024 Management View CEO Mike Morrissey highlighted significant momentum in 2024, emphasizing the company's goal of achieving $3 billion in annual cabozantinib (Cabo) revenue by 2030 and $5 billion ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...

A second trial of a clot evacuation approach to remove a hematoma in spontaneous ICH has shown some encouraging results, despite a neutral primary endpoint.

Florence has been issuing its State of Technology Enabled Clinical Trials Report for five years now, so there is contextual ...

To understand the full scope of this medication -- its effectiveness, risks, and who stands to benefit the most -- ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, chief strategy officer, Cluepoints, ...

To avoid a tug-of-war between scientific rigour and operational efficiency, we must focus on the user and data journeys of ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...